Category: Advocacy
-
Terms of Reference for the Recruitment of a Consultant for Policy Brief Development
Position Title: Consultant for Policy Brief Development on the Global Fund’s Impact in the MENA Region for GC8 Organization(s): ITPC-MENA and MENA H Coalition Duration of Consultancy: 5 effective working days Background : The Middle East and North Africa (MENA) region is experiencing a growing HIV epidemic, characterized by specific challenges in data availability and policy…
-
Call for Consultant: Acceptance Study of New Generation Long-Acting ARVs Among PLWHIV in the MENA Region
Terms of Reference (ToR) for ConsultationDemand Creation for New Generation ARVs – Acceptance Study Among PLWHIV 1. Context and Justification The Middle East and North Africa (MENA) region faces a growing HIV epidemic, characterized by increasing uncertainties regarding its incidence and consequences. Data indicate that AIDS-related deaths surged by 66% between 2005 and 2013, emphasizing…
-
The MENA H Coalition calls for sustained investments in the fight against tuberculosis in the MENA region
Joint press release FOR IMMEDIATE RELEASE MENA-H coalition urges urgent action to combat tuberculosis in the region, with emphasis on innovation and universal health coverage 2025, March 24 – On World Tuberculosis Day, the MENA-H Coalition issues an urgent call to intensify efforts to eliminate tuberculosis (TB) in the Middle East and North Africa (MENA)…
-
Call for Talents: Transform the Fight against HIV with ADP-MENA (Activists Development Program in MENA Region)
Context: The Middle East and North Africa (MENA) region continues to face major public health challenges related to HIV/AIDS. Key populations, including young people, men who have sex with men, sex workers, and injecting drug users, face significant barriers to accessing prevention and treatment services. These obstacles are exacerbated by stigma, discrimination, and a lack…
-
TERMS OF REFERENCE FOR AUDIOVISUAL AGENCY FOR GLOBAL SUMMIT 2025
ABOUT ITPC-MENA ITPC-MENA is a regional non-governmental organization operating in the MiddleEast and North Africa region bringing together a network of community activistsunited by our vision of a longer, healthier, more productive life for people living withHIV and/or HCV. ITPC-MENA’s mission is to enable communities in need, to accessHIV, HCV and TB treatment. ITPC-MENA was formed…
-
Call for Applications for the ADP (Activist Development Program) on HIV and Leadership Training in MENA Region
*Focus only on (Egypt, Lebanon, Morocco, Jordan, and Tunisia). ITPC-MENA is delighted to announce the launch of our HIV and Leadership training program designed for young activists. This program is crafted to enhance the capacities of young activists to become leaders in the fight against HIV and AIDS. HIV is a disease that affects millions…
-
ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-INCOME COUNTRIES: A REAL RACE IS STARTING AMONG PHARMACEUTICAL COMPANIES FOR MARKET SHARE AND PROFIT
Source : ITPC EECA Against the backdrop of a recent press release from Gilead announcing the signing of a voluntary license for the new drug lenacapavir, ViiV Healthcare has announced an increase in the supply of its injectable drug cabotegravir. This sequence of events inevitably raises the thought that a real race is starting among…
-
“Not in Our Name” – African HIV Treatment Advocates React to Gilead’s Voluntary Licensing Agreement on Lenacapavir
Press Statement – 4 October 2024 Today’s announcement by Gilead that six generic manufacturers have been awarded voluntary licenses for the production of lenacapavir—a groundbreaking, twice-yearly injectable for HIV prevention and potential treatment—raises significant concerns despite the inclusion of most African countries in the license territory. Exclusionary Practices: While most countries of the continent are part of…
-
Why the World Can’t Trust Pharmaceutical Companies to Ensure Global Access to Essential Medicines
Source : ITPC Global ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV prevention method—highlights why we cannot rely on pharmaceutical companies to deliver genuine global access strategies for the medicines, vaccines and diagnostics that the world needs. Lenacapavir (LEN), a twice-yearly injection, has…
-
ITPC-MENA Releases New Study: ‘Data Exclusivity under Moroccan Law’ – Implications for Access to Medicines
ITPC-MENA is pleased to announce the publication of its latest study, titled “Data Exclusivity under Moroccan Law: Implications for Access to Generic Medicines.” This comprehensive report examines the impact of Morocco’s data exclusivity provisions, introduced as part of the US-Morocco Free Trade Agreement (FTA), on the accessibility of affordable generic medicines. The study provides a detailed…